Literature DB >> 28248203

Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies.

Laurie A Silva, Terence S Dermody.   

Abstract

Chikungunya virus (CHIKV), a reemerging arbovirus, causes a crippling musculoskeletal inflammatory disease in humans characterized by fever, polyarthralgia, myalgia, rash, and headache. CHIKV is transmitted by Aedes species of mosquitoes and is capable of an epidemic, urban transmission cycle with high rates of infection. Since 2004, CHIKV has spread to new areas, causing disease on a global scale, and the potential for CHIKV epidemics remains high. Although CHIKV has caused millions of cases of disease and significant economic burden in affected areas, no licensed vaccines or antiviral therapies are available. In this Review, we describe CHIKV epidemiology, replication cycle, pathogenesis and host immune responses, and prospects for effective vaccines and highlight important questions for future research.

Entities:  

Mesh:

Year:  2017        PMID: 28248203      PMCID: PMC5330729          DOI: 10.1172/JCI84417

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  197 in total

1.  Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to the 2005-2006 explosive epidemic.

Authors:  Vidya A Arankalle; Shubham Shrivastava; Sarah Cherian; Rashmi S Gunjikar; Atul M Walimbe; Santosh M Jadhav; A B Sudeep; Akhilesh C Mishra
Journal:  J Gen Virol       Date:  2007-07       Impact factor: 3.891

2.  Emergence of chikungunya fever on the French side of Saint Martin island, October to December 2013.

Authors:  S Cassadou; S Boucau; M Petit-Sinturel; P Huc; I Leparc-Goffart; M Ledrans
Journal:  Euro Surveill       Date:  2014-04-03

3.  Experimental infection of Macaca radiata with Chikungunya virus and transmission of virus by mosquitoes.

Authors:  S D Paul; K R Singh
Journal:  Indian J Med Res       Date:  1968-06       Impact factor: 2.375

4.  A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.

Authors:  Samantha Brandler; Claude Ruffié; Chantal Combredet; Jean-Baptiste Brault; Valérie Najburg; Marie-Christine Prevost; André Habel; Erich Tauber; Philippe Desprès; Frédéric Tangy
Journal:  Vaccine       Date:  2013-06-04       Impact factor: 3.641

5.  Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.

Authors:  Katrin Ramsauer; Michael Schwameis; Christa Firbas; Matthias Müllner; Robert J Putnak; Stephen J Thomas; Philippe Desprès; Erich Tauber; Bernd Jilma; Frederic Tangy
Journal:  Lancet Infect Dis       Date:  2015-03-02       Impact factor: 25.071

6.  Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.

Authors:  Pankaj Pal; Julie M Fox; David W Hawman; Yan-Jang S Huang; Ilhem Messaoudi; Craig Kreklywich; Michael Denton; Alfred W Legasse; Patricia P Smith; Syd Johnson; Michael K Axthelm; Dana L Vanlandingham; Daniel N Streblow; Stephen Higgs; Thomas E Morrison; Michael S Diamond
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

7.  Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response.

Authors:  David W Hawman; Kristina A Stoermer; Stephanie A Montgomery; Pankaj Pal; Lauren Oko; Michael S Diamond; Thomas E Morrison
Journal:  J Virol       Date:  2013-10-16       Impact factor: 5.103

8.  Chikungunya infection in travelers.

Authors:  Patrick Hochedez; Stephane Jaureguiberry; Monique Debruyne; Philippe Bossi; Pierre Hausfater; Gilles Brucker; Francois Bricaire; Eric Caumes
Journal:  Emerg Infect Dis       Date:  2006-10       Impact factor: 6.883

9.  Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period.

Authors:  Daouda Sissoko; Denis Malvy; Khaled Ezzedine; Philippe Renault; Frederic Moscetti; Martine Ledrans; Vincent Pierre
Journal:  PLoS Negl Trop Dis       Date:  2009-03-10

10.  Human muscle satellite cells as targets of Chikungunya virus infection.

Authors:  Simona Ozden; Michel Huerre; Jean-Pierre Riviere; Lark L Coffey; Philippe V Afonso; Vincent Mouly; Jean de Monredon; Jean-Christophe Roger; Mohamed El Amrani; Jean-Luc Yvin; Marie-Christine Jaffar; Marie-Pascale Frenkiel; Marion Sourisseau; Olivier Schwartz; Gillian Butler-Browne; Philippe Desprès; Antoine Gessain; Pierre-Emmanuel Ceccaldi
Journal:  PLoS One       Date:  2007-06-13       Impact factor: 3.240

View more
  92 in total

1.  Brief report: the disability of chronic chikungunya arthritis.

Authors:  J Kennedy Amaral; Joshua B Bilsborrow; Robert T Schoen
Journal:  Clin Rheumatol       Date:  2019-04-08       Impact factor: 2.980

2.  Serotonergic Drugs Inhibit Chikungunya Virus Infection at Different Stages of the Cell Entry Pathway.

Authors:  Ellen M Bouma; Denise P I van de Pol; Ilson D Sanders; Izabela A Rodenhuis-Zybert; Jolanda M Smit
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

3.  Discovery and Characterization of 2-Nitro-5-(4-(phenylsulfonyl)piperazin-1-yl)- N-(pyridin-4-ylmethyl)anilines as Novel Inhibitors of the Aedes aegypti Kir1 ( AeKir1) Channel.

Authors:  Christopher D Aretz; M Jane Morwitzer; Austin G Sanford; Alicia M Hogan; Madelene V Portillo; Sujay V Kharade; Meghan Kramer; James B McCarthey; Renata Rusconi Trigueros; Peter M Piermarini; Jerod S Denton; Corey R Hopkins
Journal:  ACS Infect Dis       Date:  2019-03-15       Impact factor: 5.084

Review 4.  Zika, Chikungunya, and Other Emerging Vector-Borne Viral Diseases.

Authors:  Scott C Weaver; Caroline Charlier; Nikos Vasilakis; Marc Lecuit
Journal:  Annu Rev Med       Date:  2017-08-28       Impact factor: 13.739

Review 5.  Revisiting an old friend: new findings in alphavirus structure and assembly.

Authors:  Julie M Button; Shefah A Qazi; Joseph Che-Yen Wang; Suchetana Mukhopadhyay
Journal:  Curr Opin Virol       Date:  2020-07-16       Impact factor: 7.090

Review 6.  How Do Virus-Mosquito Interactions Lead to Viral Emergence?

Authors:  Claudia Rückert; Gregory D Ebel
Journal:  Trends Parasitol       Date:  2018-01-02

7.  Discovery of Widespread Host Protein Interactions with the Pre-replicated Genome of CHIKV Using VIR-CLASP.

Authors:  Byungil Kim; Sarah Arcos; Katherine Rothamel; Jeffrey Jian; Kristie L Rose; W Hayes McDonald; Yuqi Bian; Seth Reasoner; Nicholas J Barrows; Shelton Bradrick; Mariano A Garcia-Blanco; Manuel Ascano
Journal:  Mol Cell       Date:  2020-05-06       Impact factor: 17.970

8.  Epidemiological Evidence for Lineage-Specific Differences in the Risk of Inapparent Chikungunya Virus Infection.

Authors:  Fausto Bustos Carrillo; Damaris Collado; Nery Sanchez; Sergio Ojeda; Brenda Lopez Mercado; Raquel Burger-Calderon; Lionel Gresh; Aubree Gordon; Angel Balmaseda; Guillermina Kuan; Eva Harris
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

9.  Chikungunya infection: de-linking replication from symptomatology reveals the central role of muscle.

Authors:  Anne Moscona
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

10.  Antibody response patterns in chikungunya febrile phase predict protection versus progression to chronic arthritis.

Authors:  Kaustuv Nayak; Vineet Jain; Manpreet Kaur; Naushad Khan; Kamalvishnu Gottimukkala; Charu Aggarwal; Rohit Sagar; Shipra Gupta; Ramesh Chandra Rai; Kritika Dixit; Mohammad Islamuddin; Wajihul Hasan Khan; Anil Verma; Deepti Maheshwari; Yadya M Chawla; Elluri Seetharami Reddy; Harekrushna Panda; Pragati Sharma; Priya Bhatnagar; Prabhat Singh; Siva Raghavendhar B; Ashok Kumar Patel; Vinod H Ratageri; Anmol Chandele; Pratima Ray; Kaja Murali-Krishna
Journal:  JCI Insight       Date:  2020-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.